GSK to Gain Chronic Cough Drug With $2B Buyout of Bellus Health
Acquiring Bellus Health gives GSK a drug for recurrent chronic cough that could offer a better side effect profile compared to a Merck drug that addresses the same target. Bayer was also pursuing the target, but stopped work on its drug candidate last year.
Source: medcitynews.com